Russian scientists have unveiled a potential game-changer in cancer care: the Enteromix vaccine, designed to shrink tumours, train the immune system to fight cancer, and avoid the harsh side effects of chemotherapy and radiation.
The Federal Medical and Biological Agency (FMBA) announced that early clinical trials of Enteromix—an mRNA-based cancer vaccine—have shown 100% efficacy and safety.
As reported by Russian agency TASS, the announced made by FMBA head Veronika Skvortsova at the Eastern Economic Forum, signals what could be a major shift in how aggressive cancers are treated.
According to Skvortsova, the vaccine has gone through years of research, including three years of mandatory preclinical testing. Results so far suggest the vaccine is not only safe, even after multiple doses, but also highly effective. In some cases, tumours reportedly shrank or slowed their growth by 60–80%, depending on cancer type.
Enteromix will be tailored to each patient, customised to their unique RNA profile. The first rollout is expected for colorectal cancer, with further versions in development for glioblastoma (a type of brain cancer) and certain forms of melanoma (skin cancer).
Enteromix was developed using cutting-edge biotechnology, and works in two revolutionary ways. First, it acts as an oncolytic vaccine, built from a blend of four harmless viruses that directly attack cancer cells while supercharging the body's immune defences
Second, it uses personalised mRNA technology—similar to the COVID-19 vaccine platform—tailored to each patient's tumour genetic profile. This brand-new approach empowers the immune system to identify and destroy malignant cells with precision
Also Read: New study finds why acid-reducing vegan diet may help you lose weight faster
In initial trials involving 48 volunteers, scientists reported consistent tumour shrinkage, halted disease progression, and, crucially, no severe side effects.
Researchers also highlighted improved survival rates, underscoring the vaccine’s potential as a safer and more effective alternative to conventional cancer therapies.
However, experts caution that ground-breaking results in early trials are still preliminary. Expanded phase trials, independent validation, and a full regulatory review are essential before Enteromix can enter mainstream clinical use
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
